Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Dermata Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DRMA
Nasdaq
8731
https://www.dermatarx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Dermata Therapeutics Inc
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
- Apr 2nd, 2024 11:00 am
Dermata to Present at the Emerging Growth Conference on April 3, 2024
- Mar 27th, 2024 8:05 pm
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
- Mar 21st, 2024 8:05 pm
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
- Feb 6th, 2024 12:00 pm
Dermata to Present at the Emerging Growth Conference on February 7, 2024
- Feb 1st, 2024 2:00 pm
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
- Jan 4th, 2024 9:05 pm
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
- Dec 20th, 2023 9:05 pm
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
- Nov 17th, 2023 2:06 pm
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
- Nov 16th, 2023 6:30 pm
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
- Nov 16th, 2023 1:00 pm
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 9th, 2023 9:05 pm
Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial
- Oct 26th, 2023 1:00 pm
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 31st, 2023 1:00 pm
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Aug 10th, 2023 8:15 pm
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
- Jun 27th, 2023 1:00 pm
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
- Jun 13th, 2023 8:15 pm
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
- Jun 8th, 2023 1:00 pm
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
- May 26th, 2023 8:00 pm
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
- May 24th, 2023 12:00 pm
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- May 11th, 2023 8:05 pm
Scroll